Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | WRN | Q14191 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18470748 | 0.94 | HPGD (0.30) | HPGD | |
| SCHEMBL14753568 | 0.94 | POLB (0.32) | CYP2C19AKT1 | |
| SCHEMBL13531985 | 0.92 | GSK3A (0.36) | GSK3AGSK3BPTGS1PTGS2MGLL | |
| SCHEMBL12417471 | 0.88 | POLB (0.35) | GSK3AGSK3BPTGS1PTGS2MGLL | |
| SCHEMBL18470759 | 0.86 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL12417512 | 0.86 | GSK3A (0.31) | GSK3AGSK3BPTGS1PTGS2MGLL | |
| SCHEMBL16203709 | 0.83 | KDM4E (0.31) | ALDH1A1 | |
| SCHEMBL14870356 | 0.83 | MGLL (0.34) | GSK3AGSK3BPTGS1PTGS2MGLL | |
| SCHEMBL18470785 | 0.82 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL12414122 | 0.80 | GSK3A (0.41) | GSK3AGSK3BPTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2018-03-29 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9101670-B2 | Conjugates of an anti-TNF-α antibody | NEKTAR THERAPEUTICS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130059360-A1 | POLYMER-BASED COMPOSITIONS AND CONJUGATES OF ANTIMICROBIAL AGENTS | NEKTAR THERAPEUTICS (US) | 2013-03-07 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | GSK3A 3381/4885GSK3B 3928/4885PTGS1 427/4885 |
| US-20180085468-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | IL2, IL2RA, ILF2 | GSK3A 4533/4885GSK3B 4536/4885PTGS1 925/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | GSK3A 4171/4885GSK3B 4276/4885PTGS1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.